Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Yangyin Quyu is a Traditional Chinese Medicine (TCM) formula developed by the Second Affiliated Hospital of Zhejiang Chinese Medical University (also known as Xinhua Hospital of Zhejiang Province) specifically for the treatment of primary Sjogren's syndrome (pSS). The formula is designed based on the TCM therapeutic principles of supplementing Qi (Yiqi), nourishing Yin (Yangyin), and removing blood stasis (Quyu), which target the underlying pathology of Qi-Yin deficiency and blood stasis common in pSS patients. Clinical research indicates that the formula effectively alleviates symptoms of xerostomia (dry mouth) and xerophthalmia (dry eyes) while reducing systemic inflammatory markers such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and immunoglobulin G (IgG). Mechanistically, it is thought to modulate the immune response by inhibiting pro-inflammatory cytokines and potentially upregulating water channel proteins in the salivary and lacrimal glands.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi yangyin quyu.